Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

Core Insights - Kymera Therapeutics, Inc. will announce results from the Phase 1 clinical trial of KT-621 on June 2, 2025, during a video webcast [1] - KT-621 is a first-in-class oral degrader targeting STAT6, which is involved in Th2 inflammation, potentially offering a new treatment option for over 130 million patients globally suffering from various Th2 diseases [3][4] - The company is advancing KT-621 through multiple clinical trials, including a Phase 1b trial in atopic dermatitis and upcoming Phase 2b trials in asthma and moderate to severe atopic dermatitis [4] Company Overview - Kymera Therapeutics is a clinical-stage biotechnology company focused on targeted protein degradation (TPD) to develop innovative therapies for critical health issues [5] - The company aims to create a pipeline of oral small molecule degraders that provide effective and convenient treatment options for patients [5] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces [5]